What are the recommended doses for guideline‑directed medical therapy in an adult with heart failure with reduced ejection fraction?

Recommended Doses for GDMT in HFrEF

All adults with HFrEF should receive four foundational medication classes—ACEi/ARB/ARNi, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 inhibitors—initiated rapidly and titrated to target doses as tolerated, with the goal of achieving these targets within weeks to months. 1

The Four Pillars: Starting and Target Doses

1. Renin-Angiotensin System Inhibition (First-Line: ARNi)

ARNi (Preferred):

• Sacubitril-valsartan: Start 49/51 mg twice daily → Target 97/103 mg twice daily 1
• Use ARNi as first-line for NYHA class II-III symptoms 2

ACEi (if ARNi not feasible):

• Enalapril: Start 2.5 mg twice daily → Target 10-20 mg twice daily 1
• Lisinopril: Start 2.5-5 mg once daily → Target 20-40 mg once daily 1
• Ramipril: Start 1.25-2.5 mg once daily → Target 10 mg once daily 1

ARB (if ACEi causes cough/angioedema and ARNi not feasible):

• Candesartan: Start 4-8 mg once daily → Target 32 mg once daily 1
• Losartan: Start 25-50 mg once daily → Target 50-150 mg once daily 1
• Valsartan: Start 20-40 mg once daily → Target 160 mg twice daily 1

2. Beta-Blockers

Evidence-Based Beta-Blockers Only:

• Carvedilol: Start 3.125 mg twice daily → Target 25-50 mg twice daily 1
• Metoprolol succinate: Start 12.5-25 mg once daily → Target 200 mg once daily 1
• Bisoprolol: Start 1.25 mg once daily → Target 10 mg once daily 1

3. Mineralocorticoid Receptor Antagonists

• Spironolactone: Start 12.5-25 mg once daily → Target 25-50 mg once daily 1
• Eplerenone: Start 25 mg once daily → Target 50 mg once daily 1

4. SGLT2 Inhibitors

• Dapagliflozin: Start and maintain 10 mg once daily 1
• Empagliflozin: Start and maintain 10 mg once daily 1

Note: SGLT2 inhibitors require no titration—full dose from initiation.

Practical Implementation Strategy

Sequencing: "Four Drugs in Four Weeks"

Start all four medication classes simultaneously at low doses rather than waiting to achieve target doses before adding the next medication 2, 1. This approach is supported by the 2022 AHA/ACC/HFSA guidelines, which explicitly state medications may be started together without need to achieve target dosing before initiating the next medication 2.

Week 1-2: Initiate all four classes at starting doses Weeks 2-8: Uptitrate every 1-2 weeks as tolerated toward target doses 1

Titration Principles

Each medication class demonstrated mortality benefit at target doses achieved in clinical trials 1. The evidence shows:

• Beta-blockers: 34% relative risk reduction in mortality (NNT=28 over 12 months) 1
• ACEi/ARB: 17% relative risk reduction (NNT=77 over 12 months) 1
• MRA: 30% relative risk reduction (NNT=18 over 24 months) 1
• SGLT2i: 17% relative risk reduction (NNT=63 over 18 months) 1

Dose-response relationships exist: Each mg equivalent of bisoprolol (HR 0.95) and ramipril (HR 0.95) provides incremental mortality reduction 3. Patients on ≥50% target doses of multiple GDMT classes show significantly improved outcomes 4.

Managing Common Barriers

Hypotension

• Prioritize SGLT2i and MRA (minimal BP effects)
• Reduce or eliminate non-essential BP medications (e.g., amlodipine, nitrates)
• Accept systolic BP 90-100 mmHg if asymptomatic
• Consider lower ARNi/ACEi doses but maintain beta-blocker and other classes

Renal Dysfunction/Hyperkalemia

• Continue ACEi/ARB/ARNi unless K+ >5.5 mEq/L or Cr doubles
• Reduce MRA dose or hold temporarily if K+ >5.0-5.5 mEq/L
• Add potassium binders (patiromer, sodium zirconium cyclosilicate) to maintain MRA
• SGLT2i can be continued with eGFR ≥20 mL/min/1.73m²

Bradycardia

• Target heart rate 50-60 bpm is acceptable on beta-blockers
• Hold beta-blocker only if HR <50 with symptoms or heart block develops
• Prioritize beta-blocker over other rate-limiting agents

Additional Therapies (When Indicated)

Hydralazine-Isosorbide Dinitrate

For self-identified Black patients or those intolerant to ACEi/ARB/ARNi:

• Start: 20 mg isosorbide dinitrate + 37.5 mg hydralazine three times daily
• Target: 40 mg isosorbide dinitrate + 75 mg hydralazine three times daily 1
• 43% relative risk reduction in mortality (NNT=21 over 10 months) 1

Ivabradine

For sinus rhythm with HR ≥70 bpm on maximally tolerated beta-blocker:

• Start: 5 mg twice daily → Target: 7.5 mg twice daily 1

Vericiguat

For recent HF hospitalization despite GDMT:

• Start: 2.5 mg once daily → Target: 10 mg once daily 1

Digoxin

For persistent symptoms despite GDMT:

• Start: 0.125-0.25 mg daily
• Target serum level: 0.5-0.9 ng/mL 1

Critical Implementation Points

The reality gap is substantial: Only 18.2% of eligible U.S. patients receive quadruple GDMT 5, and <1% achieve target doses of all three foundational classes simultaneously over 12 months 6. This represents 113,747 preventable deaths annually in the U.S. alone 5.

Patients receiving 2-4 optimally dosed GDMT are 3.48 times more likely to respond to cardiac resynchronization therapy compared to those on zero optimally dosed therapies 7, emphasizing that medication optimization should precede device consideration.

Inpatient initiation and uptitration is both feasible and beneficial, with improved 30-day hospitalization-free survival and 1-year survival when medications are started or increased during HF hospitalizations 4.

The evidence unequivocally supports aggressive, early, and comprehensive implementation of all four medication classes with structured uptitration to target doses—not sequential cautious addition over months to years.